On May 29, 2025, Mirum Pharmaceuticals held its Annual Meeting where stockholders elected new directors, ratified Ernst & Young as the accounting firm, and approved executive compensation. Key votes included 30.8 million for Michael Grey as a director and 43.1 million supporting the accounting firm ratification.